Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 5431-5440

  Wu, Xin ^a,b   Tai, Zongguang ^a   Zhu, Quangang ^c   Fan, Wei ^d   Ding, Baoyue ^e   Zhang, Wei ^a,f   Zhang, Lijuan ^a   Yao, Chong ^a   Wang, Xiaoyu ^a   Ding, Xueying ^b   Li, Qin ^b   Li, Xiaoyu ^b   Liu, Gaolin ^b   Liu, Jiyong ^a   Gao, Shen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d No 425 Hospital of Chinese PLA   (China)

^e JIAXING UNIVERSITY   (China)

^f Department of Pharmaceutics   (China)

Author keywords

Aptamer; miRNA; Polyamidoamine; Prostate cancer; Prostate specific membrane antigen; Targeted delivery

Indexed keywords

APTAMER; MICRORNA; MICRORNA 15A; MICRORNA 16 1; NANOPARTICLE; POLYAMIDOAMINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CHEMISTRY; BLOOD TOXICITY; CANCER GENE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEASIBILITY STUDY; IN VIVO STUDY; INTERNALIZATION; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIVER FUNCTION; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROSTATE CANCER; SURVIVAL TIME; TISSUE DISTRIBUTION; TOXICITY TESTING; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT CHANGE; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PROSTATE TUMOR;

ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; BODY WEIGHT; DRUG CARRIERS; GLUTAMATE CARBOXYPEPTIDASE II; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NANOPARTICLES; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84911897175     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S71101     Document Type: Article

References (31)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Yang YF, Xue SY, Lu ZZ, et al. Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer. Gene Ther. 2014;21(8):723-731.
3. Azab BM, Dash R, Das SK, et al. Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV). J Cell Physiol. 2014;229(1):34-43.
4. Jiang Z, Sun C, Yin Z, et al. Comparison of two kinds of nanomedicine for targeted gene therapy: premodified or postmodified gene delivery systems. Int J Nanomedicine. 2012;7:2019-2031.
5. Xue HY, Wong HL. Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted, and safer siRNA therapy of prostate cancer in an all-in-one manner. ACS Nano. 2011;5(9):7034-7047.
6. Wu X, Ding B, Gao J, et al. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine. 2011;6:1747-1756.
7. Xiang B, Dong DW, Shi NQ, et al. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials. 2013;34(28):6976-6991.
8. Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence. 2010;1(1):4.
9. Su Y, Yu L, Liu N, et al. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth. Cancer Lett. 2013;338(2):282-291.
10. Civenni G, Malek A, Albino D, et al. RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer Res. 2013;73(22):6816-6827.
11. Yao V, Berkman CE, Choi JK, O'Keefe DS, Bacich DJ. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate. 2010;70(3):305-316.
12. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540-547.
13. Moffatt S, Cristiano RJ. PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells. Int J Pharm. 2006;317(1):10-13.
14. Barve A, Jin W, Cheng K. Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release. 2014;187:118-132.
15. Dassie JP, Hernandez LI, Thomas GS, et al. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Mol Ther. Epub 2014 Jun 23.
16. Huang R, Ke W, Han L, et al. Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J Cereb Blood Flow Metab. 2009;29(12):1914-1923.
17. Liu J, Shapiro JI. Endocytosis and signal transduction: basic science update. Biol Res Nurs. 2003;5(2):117-128.
18. Kim HR, Gil S, Andrieux K, et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci. 2007;64(3):356-364.
19. Visser CC, Stevanović S, Heleen Voorwinden L, et al. Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target. 2004;12(3):145-150.
20. Schwarzenböck S, Sachs D, Souvatzoglou M, et al. [[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model]. Nuklearmedizin. 2013;52(4):141-147. German.
21. Xin H, Jiang X, Gu J, et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials. 2011;32(18):4293-4305.
22. Xin H, Chen L, Gu J, et al. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ε-caprolactone) nanoparticles: In vitro and in vivo evaluation. Int J Pharm. 2010;402(1-2):238-247.
23. Jiang T, Zhou C, Gu J, et al. Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA. Cancer Lett. 2013;337(1):133-142.
24. Fang J, Sawa T, Akaike T, Greish K, Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer. 2004;109(1):1-8.
25. Cabral H, Miyata K, Kishimura A. Nanodevices for studying nano-pathophysiology. Adv Drug Deliv Rev. 2014;74C:35-52.
26. Dassie JP, Liu XY, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009;27(9):839-849.
27. Hao Z, Fan W, Hao J, et al. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Drug Deliv. Epub 2014 Jun 3.
28. Taghdisi SM, Danesh NM, Sarreshtehdar Emrani A, et al. Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer. J Drug Target. 2013;21(8):739-744.
29. Min K, Jo H, Song K, et al. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials. 2011;32(8):2124-2132.
30. Markowicz-Piasecka M, Luczak E, Chałubiński M, Broncel M, Mikiciuk-Olasik E, Sikora J. Studies towards biocompatibility of PAMAM dendrimers - Overall hemostasis potential and integrity of the human aortic endothelial barrier. Int J Pharm. 2014;473(1-2):158-169.
31. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14(11):1271-1277.